Beranda › Limfoma Burkitt › North Carolina › Durham
Uji klinis Limfoma Burkitt di Durham, NC
10 studi untuk Limfoma Burkitt mencari peserta di lokasi sekitar Durham (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Menerima pesertaFase 2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Menerima pesertaFase 3
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Menerima pesertaFase 2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Menerima pesertaFase 3
- Duke University, Durham
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Menerima pesertaFase 2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Menerima pesertaFase 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Menerima pesertaFase 1/2
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill · 10 mi jauhnya
Registry of Older Patients With Cancer
Menerima pesertaStudi observasional
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi jauhnya
Study of SGR-1505 in Mature B-Cell Neoplasms
Menerima pesertaFase 1
- Duke University, Durham
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Menerima pesertaStudi observasional
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi jauhnya
Uji klinis Limfoma Burkitt di kota lain
- Houston, TX21 studi
- Philadelphia, PA16 studi
- Milwaukee, WI16 studi
- Chicago, IL15 studi
- Cincinnati, OH13 studi
- New York City, NY13 studi
- Atlanta, GA12 studi
- Aurora, CO11 studi
- Seattle, WA11 studi
- Boston, MA10 studi
- Kansas City, MO10 studi
- Los Angeles, CA10 studi
Studi lain di Durham
- Kanker Payudara64 studi
- Kanker (semua jenis)58 studi
- Kanker Paru Non-Sel Kecil39 studi
- Mieloma Multipel37 studi
- Leukemia Mieloid Akut33 studi
- Kanker Metastatik33 studi
- Kanker Prostat32 studi
- Kanker Paru32 studi
- Kanker Kolorektal28 studi
- Kanker Ovarium27 studi
- Leukemia Limfositik Kronis27 studi
- Gagal Jantung26 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.